Additional Study Information: Are you suffering from chronic fatigue that began after you were diagnosed and treated with antibiotics for Lyme Disease? This new treatment research study investigates whether disulfiram, commonly known as "Antabuse", has the potential to be used as a treatment option for patients experiencing chronic post-treatment Lyme symptoms. This well-known, FDA approved drug is currently used to help individuals with alcohol dependence resist consumption; however, new scientific research has demonstrated that disulfiram is a potent killer of the Lyme bacteria in the laboratory setting. The primary goals of this study are to assess safety, side-effects, and effectiveness of disulfiram in reducing symptoms in patients with post-treatment Lyme symptoms. This study will take place over the course of 16 weeks and will enroll patients with several Telehealth visits and only 2 in-person visits to our research center in New York City. Participants will be placed on either a 4-week or 8-week, fixed flexible dosing regimen of disulfiram. Patients will be required to visit their local Quest Diagnostics laboratory center for close monitoring throughout the trial.